Geode Capital Management LLC Boosts Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Geode Capital Management LLC increased its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 2.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,389,240 shares of the company's stock after acquiring an additional 45,930 shares during the quarter. Geode Capital Management LLC owned about 2.35% of Intellia Therapeutics worth $27,865,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Whipplewood Advisors LLC bought a new position in shares of Intellia Therapeutics during the 4th quarter valued at approximately $40,000. Jones Financial Companies Lllp raised its stake in Intellia Therapeutics by 140.9% during the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock valued at $45,000 after purchasing an additional 2,280 shares in the last quarter. Daiwa Securities Group Inc. raised its stake in Intellia Therapeutics by 80.6% during the fourth quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company's stock valued at $60,000 after purchasing an additional 2,299 shares in the last quarter. KBC Group NV lifted its position in Intellia Therapeutics by 62.4% during the fourth quarter. KBC Group NV now owns 6,093 shares of the company's stock valued at $71,000 after purchasing an additional 2,340 shares during the last quarter. Finally, AdvisorNet Financial Inc grew its stake in shares of Intellia Therapeutics by 96.4% in the 4th quarter. AdvisorNet Financial Inc now owns 10,085 shares of the company's stock worth $118,000 after buying an additional 4,950 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Price Performance

Shares of NTLA stock traded up $0.28 during mid-day trading on Wednesday, hitting $8.59. The stock had a trading volume of 661,871 shares, compared to its average volume of 2,362,529. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $28.18. The firm's 50-day moving average is $8.83 and its two-hundred day moving average is $12.01. The firm has a market capitalization of $889.21 million, a P/E ratio of -1.58 and a beta of 2.23.

Analysts Set New Price Targets

Several brokerages have recently issued reports on NTLA. The Goldman Sachs Group restated a "sell" rating and set a $9.00 target price on shares of Intellia Therapeutics in a research report on Friday, February 28th. BMO Capital Markets decreased their price objective on Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating on the stock in a research report on Friday, January 10th. Barclays dropped their target price on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Citigroup increased their price target on Intellia Therapeutics from $12.00 to $14.00 and gave the company a "neutral" rating in a report on Friday, February 28th. Finally, Wedbush reaffirmed a "neutral" rating and set a $10.00 price objective (down from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $36.68.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.